AR018174A1 - Uso del interferon gamma para la manufactura de un medicamento util para el tratamiento de hipertrofia cardiaca, un producto farmaceutico que contieney el metodo para hacer una composicion farmaceutica para dicho tratamiento. - Google Patents
Uso del interferon gamma para la manufactura de un medicamento util para el tratamiento de hipertrofia cardiaca, un producto farmaceutico que contieney el metodo para hacer una composicion farmaceutica para dicho tratamiento.Info
- Publication number
- AR018174A1 AR018174A1 ARP990101482A ARP990101482A AR018174A1 AR 018174 A1 AR018174 A1 AR 018174A1 AR P990101482 A ARP990101482 A AR P990101482A AR P990101482 A ARP990101482 A AR P990101482A AR 018174 A1 AR018174 A1 AR 018174A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- cardiac hypertrophy
- pharmaceutical
- gamma
- manufacture
- Prior art date
Links
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 4
- 208000006029 Cardiomegaly Diseases 0.000 abstract 4
- 102000008070 Interferon-gamma Human genes 0.000 abstract 4
- 108010074328 Interferon-gamma Proteins 0.000 abstract 4
- 229960003130 interferon gamma Drugs 0.000 abstract 4
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010067171 Regurgitation Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de interferon-gamma (IFN-gamma) para la manufactura de un medicamento util de tratamiento de hipertrofia cardíaca, caracterizado porque comprende,una cantidad terapéuticamente efectiva de interferon gamma (IFN-gamma) y un vehículo farmacéutico dehipertrofia cardíaca, un productofarmacéutico que lo contiene y el método para hacer una composicion farmacéutica para dicho tratamiento. La hipertrofia cardíaca puede resultar de unavariedad de diversas condiciones patologicas, incluyendo infartacion de miocardio, hipertension, cardiomiopatía hipertrofica y regurgitacion valvular.El tratamiento se extiende a todas las etapas de la progresion de la hipertrofia cardíaca, con o sin el dano estructural del musculo cardíaco,sin consideracion al desorden cardíaco precedente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8044898P | 1998-04-02 | 1998-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018174A1 true AR018174A1 (es) | 2001-10-31 |
Family
ID=22157456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101482A AR018174A1 (es) | 1998-04-02 | 1999-03-31 | Uso del interferon gamma para la manufactura de un medicamento util para el tratamiento de hipertrofia cardiaca, un producto farmaceutico que contieney el metodo para hacer una composicion farmaceutica para dicho tratamiento. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6187304B1 (es) |
| EP (2) | EP1067958B1 (es) |
| JP (2) | JP5030329B2 (es) |
| CN (1) | CN1201814C (es) |
| AR (1) | AR018174A1 (es) |
| AT (2) | ATE332144T1 (es) |
| AU (1) | AU757910B2 (es) |
| BR (1) | BR9909422A (es) |
| CA (1) | CA2325442C (es) |
| DE (2) | DE69939723D1 (es) |
| DK (2) | DK1067958T3 (es) |
| ES (2) | ES2314786T3 (es) |
| IL (1) | IL138812A0 (es) |
| NZ (1) | NZ506854A (es) |
| TW (1) | TWI243682B (es) |
| WO (1) | WO1999051260A2 (es) |
| ZA (1) | ZA200004854B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020192659A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| BR9909422A (pt) * | 1998-04-02 | 2001-09-11 | Genentech Inc | Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico |
| ATE376837T1 (de) * | 1999-07-12 | 2007-11-15 | Genentech Inc | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| US7838225B2 (en) * | 1999-10-29 | 2010-11-23 | Hologic, Inc. | Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase |
| US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
| US8110218B2 (en) * | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
| AU2002310922A1 (en) * | 2001-05-04 | 2002-11-18 | Institute Of Molecular And Cell Biology | Interferons in the treatment of ischemia |
| US20050079156A1 (en) * | 2001-11-06 | 2005-04-14 | Grace Wong | Method of treating endometreosis |
| WO2003068260A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| KR101160780B1 (ko) * | 2002-08-29 | 2012-06-27 | 산텐 세이야꾸 가부시키가이샤 | Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제 |
| WO2004045644A1 (ja) * | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| WO2009154770A2 (en) * | 2008-06-18 | 2009-12-23 | The Texas A & M University System | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage |
| USD647411S1 (en) | 2011-01-12 | 2011-10-25 | Rain Bird Corporation | Water timer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096705A (en) | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
| US5582824A (en) | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4929544A (en) | 1982-04-23 | 1990-05-29 | Sri International | Reagents, methods, and test kit for diagnosing/monitoring cancer in humans |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| US4944941A (en) | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
| SE462364B (sv) | 1988-09-30 | 1990-06-18 | Goeran Hansson | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos |
| DK0502997T3 (da) | 1989-12-01 | 1995-07-17 | Childrens Medical Center | Behandling af atopiske sygdomme med gamma-interferon |
| US6207641B1 (en) * | 1995-03-10 | 2001-03-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases |
| US5573762A (en) | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
| WO1997007820A1 (fr) * | 1995-08-30 | 1997-03-06 | Toray Industries, Inc. | Remede destine aux maladies cardiaques |
| BR9909422A (pt) * | 1998-04-02 | 2001-09-11 | Genentech Inc | Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico |
-
1999
- 1999-03-19 BR BR9909422-3A patent/BR9909422A/pt not_active IP Right Cessation
- 1999-03-19 DK DK99912711T patent/DK1067958T3/da active
- 1999-03-19 DK DK06013719T patent/DK1702623T3/da active
- 1999-03-19 EP EP99912711A patent/EP1067958B1/en not_active Expired - Lifetime
- 1999-03-19 DE DE69939723T patent/DE69939723D1/de not_active Expired - Lifetime
- 1999-03-19 US US09/273,099 patent/US6187304B1/en not_active Expired - Lifetime
- 1999-03-19 AT AT99912711T patent/ATE332144T1/de active
- 1999-03-19 WO PCT/US1999/006032 patent/WO1999051260A2/en not_active Ceased
- 1999-03-19 AU AU31024/99A patent/AU757910B2/en not_active Ceased
- 1999-03-19 DE DE69932235T patent/DE69932235T2/de not_active Expired - Lifetime
- 1999-03-19 AT AT06013719T patent/ATE410181T1/de active
- 1999-03-19 CA CA2325442A patent/CA2325442C/en not_active Expired - Fee Related
- 1999-03-19 ES ES06013719T patent/ES2314786T3/es not_active Expired - Lifetime
- 1999-03-19 EP EP06013719A patent/EP1702623B1/en not_active Expired - Lifetime
- 1999-03-19 NZ NZ506854A patent/NZ506854A/en not_active IP Right Cessation
- 1999-03-19 JP JP2000542031A patent/JP5030329B2/ja not_active Expired - Fee Related
- 1999-03-19 CN CNB99804881XA patent/CN1201814C/zh not_active Expired - Fee Related
- 1999-03-19 ES ES99912711T patent/ES2267258T3/es not_active Expired - Lifetime
- 1999-03-19 IL IL13881299A patent/IL138812A0/xx not_active IP Right Cessation
- 1999-03-31 AR ARP990101482A patent/AR018174A1/es unknown
- 1999-08-10 TW TW088105269A patent/TWI243682B/zh not_active IP Right Cessation
-
2000
- 2000-09-13 ZA ZA200004854A patent/ZA200004854B/xx unknown
- 2000-11-16 US US09/715,739 patent/US6989364B1/en not_active Expired - Fee Related
-
2009
- 2009-08-04 JP JP2009181954A patent/JP2009256375A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK1702623T3 (da) | 2009-01-19 |
| ES2314786T3 (es) | 2009-03-16 |
| EP1702623A3 (en) | 2007-01-10 |
| TWI243682B (en) | 2005-11-21 |
| AU3102499A (en) | 1999-10-25 |
| CN1201814C (zh) | 2005-05-18 |
| NZ506854A (en) | 2003-07-25 |
| ZA200004854B (en) | 2001-09-26 |
| ES2267258T3 (es) | 2007-03-01 |
| CA2325442C (en) | 2011-10-11 |
| EP1702623B1 (en) | 2008-10-08 |
| JP2002510645A (ja) | 2002-04-09 |
| EP1067958A2 (en) | 2001-01-17 |
| IL138812A0 (en) | 2001-10-31 |
| ATE410181T1 (de) | 2008-10-15 |
| JP2009256375A (ja) | 2009-11-05 |
| EP1702623A2 (en) | 2006-09-20 |
| US6187304B1 (en) | 2001-02-13 |
| WO1999051260A3 (en) | 1999-12-09 |
| EP1067958B1 (en) | 2006-07-05 |
| HK1036019A1 (en) | 2001-12-21 |
| JP5030329B2 (ja) | 2012-09-19 |
| ATE332144T1 (de) | 2006-07-15 |
| US6989364B1 (en) | 2006-01-24 |
| HK1099197A1 (en) | 2007-08-10 |
| DE69932235T2 (de) | 2007-06-14 |
| WO1999051260A2 (en) | 1999-10-14 |
| DE69932235D1 (de) | 2006-08-17 |
| CN1300221A (zh) | 2001-06-20 |
| AU757910B2 (en) | 2003-03-13 |
| CA2325442A1 (en) | 1999-10-14 |
| DK1067958T3 (da) | 2006-11-06 |
| DE69939723D1 (de) | 2008-11-20 |
| BR9909422A (pt) | 2001-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0479903T3 (da) | Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere | |
| ATE189400T1 (de) | Knochenwachstumsfördernde zusammensetzung | |
| MX9505182A (es) | Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p. | |
| AR033796A1 (es) | Composicion farmaceutica | |
| BE901737A (fr) | Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue. | |
| ES2052066T3 (es) | Mejoras en o relacionadas con compuestos organicos. | |
| PE20001296A1 (es) | El uso de una combinacion de tipranavir y ritonavir para mejorar la farmacocinetica del tipranavir | |
| ES2010561A6 (es) | Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina. | |
| ES2193233T3 (es) | Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica. | |
| CO5050328A1 (es) | Sistema solvente para la mejor penetracion de compuestos farmaceuticos | |
| ES2103493T3 (es) | Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo. | |
| MX340217B (es) | Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon. | |
| ES2165232T3 (es) | Sistema terapeutico transdermico (tts) que contiene oxibutinina. | |
| EP1702623A3 (en) | Use of interferon gamma for the treatment of cardiac hypertrophy | |
| UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
| MX9705916A (es) | Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc. | |
| AR015230A1 (es) | Composicion cosmetica que contiene un compuesto de actividad estimuladora de la produccion de interleuquina-6, cepa rhodotorula sebr 2002, procedimiento depreparacion de un extracto, composicion obtenida, utilizacion de un compuesto de actividad estimuladora y metodo de tratamiento cosmetico. | |
| DE3875611D1 (de) | Pharmazeutische zusammensetzungen. | |
| ES2171439T3 (es) | Composicion a base de aminoacidos para el tratamiento de infecciones. | |
| ES2191206T3 (es) | Nueva utilizacion de la creatina. | |
| ES526300A0 (es) | Procedimiento para la obtencion de una composicion farmaceutica conteniendo un agente fibrino litico y un factor de difusion, util para el tratamiento del infarto de miocardio. | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| AR022620A1 (es) | Aroil aminoacil pirroles para ser usados en el tratamiento de dolor neuropatico | |
| ES2031462T3 (es) | Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. | |
| ES2053683T3 (es) | Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |